Project Grant HT94252410188
Award Date
4/1/24
Completion Date
3/31/27
Dollars Obligated
$700K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The federal Project Grant award of $932,918 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Washington to determine the role of somatic mosaicism in ovarian cancer predisposition. The grant, awarded on September 30, 2024 with an ultimate completion date of September 29, 2028, will enable the University of Washington to conduct innovative scientific studies to improve health outcomes for military...
The University of Washington received a $622,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the fibrolamellar carcinoma tumor microenvironment using human tumor slice cultures. The award has a performance period from July 1, 2024 to June 30, 2026. Through this funding, the University of Washington will investigate innovative approaches to improve understanding of the fibrolamellar carcinoma tumor...
The Department of Defense's Defense Health Agency awarded a $1,127,375 Project Grant to The Washington University Office of Sponsored Research Services Division under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from Sep 30, 2023 to Sep 29, 2027, will fund research on "REPLICATION DRIVEN VULNERABILITIES IN CYCLIN E OVEREXPRESSING OVARIAN CANCERS". As a prominent research institution with expertise in biomedical sciences, The Washington...
This Project Grant award, valued at $543,285.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the University of Washington will conduct research to develop new FDA-approved combination therapies for transforming the treatment of rhabdomyosarcoma, a rare...
This Project Grant award of $1,412,000 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a biorepository and community development project to characterize aggressive urothelial cancer variants. The University of Washington, as the prime awardee, will conduct this research over a period of approximately 4 years, from September 2024 through August 2028. The project aims to expand understanding of aggressive forms of urothelial (bladder)...
This Project Grant award, valued at $466,500.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research aimed at "LEVERAGING THE OVARIAN TUMOR MICROENVIRONMENT FOR EARLY DETECTION STRATEGIES" at The Washington University in University City, Missouri. The research, which will be conducted over a period of 2 years from August 1, 2025 to July 31, 2027, is focused on developing innovative early...
The University of Washington was awarded a $1,166,250 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The three-year award will support long-read DNA sequencing and targeted RNA sequencing to identify previously undetectable classes of mutations in families with lethal prostate cancer. Through innovative biomedical research techniques, the project aims to transform healthcare for service...
This federal Project Grant award of $459,747.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Wisconsin-Madison to define the effect of copy number amplification on the regulation of oncogenes in high-grade serous ovarian carcinoma. The research will examine the contributions of superenhancers at the 8q22 region, with the goal of advancing scientific understanding and potential treatment...
The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
The University of Washington received a three-year, $708,603 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research into Differential ADAR1 Dependency in Breast Cancer, which aims to reveal therapeutic opportunities through regulation of MDM2 and ferropotosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and...